Narval has raised $4.0 million in new investment capital to advance its innovative drug development platform. The company is pioneering a new generation of antibody drugs that utilize synthetic proteins. These proteins are designed to mimic the activity of traditional antibodies and offer a novel approach to therapeutic delivery.
Narval's technology focuses on treatments that can be delivered through mucosal and skin tissues, providing a less invasive alternative for patients. This method targets diseases affecting critical areas such as the eyes, lungs, and skin. The secured funding is expected to accelerate the development of Narval's pipeline of synthetic protein-based therapies and expand its research capabilities.
This investment underscores confidence in Narval's unique approach to drug delivery and its potential to address unmet medical needs across various conditions. The capital will be deployed to further validate its platform and advance its therapeutic candidates through preclinical and early clinical stages. Narval plans to use the funds for growth initiatives, including expanding its scientific team and scaling its laboratory operations. The company is focused on bringing its innovative treatments closer to patients by progressing its drug candidates towards clinical trials in the coming years.
